Sixth Element Capital is a venture capital investment firm based in Herts, United Kingdom, founded in 2010. The firm focuses on the healthcare sector, specifically targeting innovations in cancer therapy and diagnosis. It is currently managing its inaugural fund, the £70 million CRT Pioneer Fund, which aims to advance the development of future cancer treatment and diagnostic solutions.
NeoPhore Ltd is a biotechnology company based in Cambridge, United Kingdom, that specializes in the discovery and development of small molecule therapies aimed at treating cancer by stimulating the immune system. Founded in 2017, NeoPhore focuses on creating novel therapeutics that target genetic mechanisms to generate neoantigens. These neoantigens are designed to enhance the immune response against tumor cells, potentially exploiting vulnerabilities in their defense mechanisms. By harnessing this approach, NeoPhore aims to improve clinical outcomes for cancer patients through innovative immuno-oncology treatments.
NeoPhore
Series B in 2023
NeoPhore Ltd is a biotechnology company based in Cambridge, United Kingdom, that specializes in the discovery and development of small molecule therapies aimed at treating cancer by stimulating the immune system. Founded in 2017, NeoPhore focuses on creating novel therapeutics that target genetic mechanisms to generate neoantigens. These neoantigens are designed to enhance the immune response against tumor cells, potentially exploiting vulnerabilities in their defense mechanisms. By harnessing this approach, NeoPhore aims to improve clinical outcomes for cancer patients through innovative immuno-oncology treatments.
NeoPhore
Series B in 2021
NeoPhore Ltd is a biotechnology company based in Cambridge, United Kingdom, that specializes in the discovery and development of small molecule therapies aimed at treating cancer by stimulating the immune system. Founded in 2017, NeoPhore focuses on creating novel therapeutics that target genetic mechanisms to generate neoantigens. These neoantigens are designed to enhance the immune response against tumor cells, potentially exploiting vulnerabilities in their defense mechanisms. By harnessing this approach, NeoPhore aims to improve clinical outcomes for cancer patients through innovative immuno-oncology treatments.
Azeria Therapeutics
Series B in 2019
Azeria Therapeutics Limited is a drug discovery company based in Cambridge, United Kingdom, founded in 2017. The company focuses on developing treatments for patients suffering from hormone-resistant breast and prostate cancer, addressing significant unmet clinical needs in this area. Azeria specializes in a pipeline of small molecules that selectively inhibit pioneer factors, which are crucial in the development and progression of these cancers. By targeting these factors, the company aims to provide more effective treatment options for healthcare professionals managing various cancer types, thereby improving outcomes for patients.
Azeria Therapeutics
Series A in 2018
Azeria Therapeutics Limited is a drug discovery company based in Cambridge, United Kingdom, founded in 2017. The company focuses on developing treatments for patients suffering from hormone-resistant breast and prostate cancer, addressing significant unmet clinical needs in this area. Azeria specializes in a pipeline of small molecules that selectively inhibit pioneer factors, which are crucial in the development and progression of these cancers. By targeting these factors, the company aims to provide more effective treatment options for healthcare professionals managing various cancer types, thereby improving outcomes for patients.
AdoRx Therapeutics
Series A in 2018
AdoRx Therapeutics Limited is a drug discovery company based in Edinburgh, United Kingdom, focused on developing new therapeutics for cancer by modulating the adenosine pathway. Founded in 2017, the company targets the high levels of adenosine present in the tumor microenvironment, which allow cancer cells to evade the immune system. AdoRx's lead programs concentrate on creating tailored adenosine receptor antagonists designed to counteract the effects of elevated adenosine levels. The leadership team at AdoRx has extensive experience in drug discovery, having previously developed over 25 clinical candidates. The company is supported by investment from Epidarex Capital and Sixth Element Capital, enhancing its capacity to advance innovative cancer treatments.
NeoPhore
Venture Round in 2017
NeoPhore Ltd is a biotechnology company based in Cambridge, United Kingdom, that specializes in the discovery and development of small molecule therapies aimed at treating cancer by stimulating the immune system. Founded in 2017, NeoPhore focuses on creating novel therapeutics that target genetic mechanisms to generate neoantigens. These neoantigens are designed to enhance the immune response against tumor cells, potentially exploiting vulnerabilities in their defense mechanisms. By harnessing this approach, NeoPhore aims to improve clinical outcomes for cancer patients through innovative immuno-oncology treatments.
Macrophage Pharma
Series A in 2017
Macrophage Pharma Limited is an immuno-oncology company based in Berkhamsted, United Kingdom, established in 2014. The company specializes in discovering and developing innovative therapies aimed at enhancing anti-tumor immune responses. Its technology platform focuses on the selective delivery of small molecule drugs to tumor-associated macrophages, which activates the body's natural immune system to combat cancer. By harnessing this targeted approach, Macrophage Pharma aims to improve treatment outcomes for patients facing cancer.
Achilles Therapeutics
Seed Round in 2016
Achilles Therapeutics Ltd. is a biopharmaceutical company based in London, United Kingdom, focused on developing patient-specific immunotherapies to treat cancer. Founded in 2016, the company creates personalized vaccines and T cell therapies that harness the immune system to target and eliminate cancer cells. By identifying truncal tumor neo-antigens and other cancer-specific markers, Achilles Therapeutics aims to develop next-generation therapies that selectively attack tumors while sparing healthy tissues. Currently, the company is conducting two clinical trials: the CHIRON trial for patients with non-small-cell lung cancer and the THETIS trial for those with recurrent or metastatic melanoma.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.